FDA approves Inovio’s Voceryq, sending shares higher
BROBROK News · Based on reporting by DiarioBitcoin ·
The FDA granted accelerated approval to Voceryq, Inovio’s INO-3107 therapy, to reduce surgery frequency in adults with recurrent respiratory papillomatosis. Reuters reported that Inovio shares jumped 215% in after-hours trading after the announcement.
Key points
- Vocyryq is the commercial name for INO-3107.
- The approved use is to reduce surgery frequency in adults with recurrent respiratory papillomatosis.
- Inovio said this is its first FDA-approved product.
- The company highlighted phase 1/2 data showing fewer surgeries in some patients.
- The article also showed an INO move of -21.95%, but without a clear time frame.
Why it matters
This is a regulatory milestone for Inovio and may affect how the market values the company. The move also shows how FDA decisions can quickly reshape sentiment around biotech stocks.
Original headline: “La FDA aprueba Voceryq, el primer producto de Inovio, y sus acciones suben 215%”
Read the original on DiarioBitcoin
Summary and analysis written by BROBROK News from the original report. Read the full story on the source website. Not investment advice.